Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Current Assets: 2017-2024

Historic Current Assets for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $210.7 million.

  • Cidara Therapeutics' Current Assets rose 182.46% to $442.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $442.8 million, marking a year-over-year increase of 182.46%. This contributed to the annual value of $210.7 million for FY2024, which is 246.29% up from last year.
  • Cidara Therapeutics' Current Assets amounted to $210.7 million in FY2024, which was up 246.29% from $60.9 million recorded in FY2023.
  • Cidara Therapeutics' Current Assets' 5-year high stood at $210.7 million during FY2024, with a 5-year trough of $45.1 million in FY2022.
  • Its 3-year average for Current Assets is $105.6 million, with a median of $60.9 million in 2023.
  • As far as peak fluctuations go, Cidara Therapeutics' Current Assets tumbled by 37.11% in 2022, and later soared by 246.29% in 2024.
  • Cidara Therapeutics' Current Assets (Yearly) stood at $57.2 million in 2020, then climbed by 25.37% to $71.7 million in 2021, then slumped by 37.11% to $45.1 million in 2022, then skyrocketed by 34.95% to $60.9 million in 2023, then soared by 246.29% to $210.7 million in 2024.